Samalizumab

N/A

Report date: 2022/08/29 20:00:24

Base Information

Drug NameSamalizumab
Drug Alias NameALXN-6000
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionOX-2 membrane glycoprotein inhibitorsImmunomodulators
TargetsOX-2 membrane glycoprotein
Therapy Area/IndicationsSolid tumoursMultiple MyelomaLeukemia, Lymphocytic, Chronic, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesThe Leukemia & Lymphoma SocietyAlexion Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAlexion Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsSolid tumoursMultiple MyelomaLeukemia, Lymphocytic, Chronic, B-Cell

Other Information

ATC CodeN/A
Related LinksN/A